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To estimate effectiveness of seasonal trivalent and 
monovalent inﬂ  uenza vaccines against pandemic inﬂ  uenza 
A (H1N1) 2009 virus, we conducted a test-negative case–
control study in Victoria, Australia, in 2010. Patients seen 
for inﬂ   uenza-like illness by general practitioners in a 
sentinel surveillance network during 2010 were tested for 
inﬂ  uenza; vaccination status was recorded. Case-patients 
had positive PCRs for pandemic (H1N1) 2009 virus, and 
controls had negative inﬂ  uenza test results. Of 319 eligible 
patients, test results for 139 (44%) were pandemic (H1N1) 
2009 virus positive. Adjusted effectiveness of seasonal 
vaccine against pandemic (H1N1) 2009 virus was 79% 
(95% conﬁ   dence interval 33%–93%); effectiveness of 
monovalent vaccine was 47% and not statistically signiﬁ  cant. 
Vaccine effectiveness was higher among adults. Despite 
some limitations, this study indicates that the ﬁ  rst seasonal 
trivalent inﬂ  uenza vaccine to include the pandemic (H1N1) 
2009 virus strain provided signiﬁ   cant protection against 
laboratory-conﬁ  rmed pandemic (H1N1) 2009 infection.
A
fter the emergence and rapid global spread of pandemic 
inﬂ  uenza A (H1N1) 2009 virus, development of a 
pandemic (H1N1) 2009–speciﬁ   c vaccine began (1). A 
candidate reassortant vaccine virus, derived from the A/
California/7/2009 (H1N1)v virus as recommended by 
the World Health Organization, was used to produce a 
monovalent, unadjuvanted, inactivated, split-virus vaccine 
for Australia (2,3). The national monovalent pandemic 
(H1N1) 2009 vaccination program in Australia ran from 
September 30, 2009, through December 31, 2010, and 
vaccination was publicly funded for all persons in Australia 
>6 months of age (4,5).
In September 2009, the World Health Organization 
recommended that trivalent inﬂ  uenza vaccines for use in 
the 2010 inﬂ  uenza season (Southern Hemisphere winter) 
contain A/California/7/2009 (H1N1)–like virus, A/
Perth/16/2009 (H3N2)–like virus, and B/Brisbane/60/2008 
(of the B/Victoria/2/87 lineage) virus (6). Since March 
2010, the Australian Government has provided free 
seasonal inﬂ  uenza vaccination to all Australia residents 
>65 years of age, all Aboriginal and Torres Strait Islander 
persons >50 years, all Aboriginal and Torres Strait Islander 
persons 15–49 years with medical risk factors, persons 
>6 months with conditions that predispose them to severe 
inﬂ  uenza, and pregnant women (7). Inﬂ  uenza vaccination is 
also recommended, but not funded, for persons who might 
transmit inﬂ  uenza to those at high risk for complications 
from inﬂ   uenza, persons who provide essential services, 
travelers, and anyone >6 months of age for whom reducing 
the likelihood of becoming ill with inﬂ  uenza is desired. 
Individual industries are also advised to consider the 
beneﬁ   ts of offering inﬂ   uenza vaccine in the workplace 
(8). Because pandemic (H1N1) 2009 was expected to 
be the dominant strain in 2010, the monovalent vaccine 
continued to be used despite the availability of the seasonal 
vaccine, particularly by persons who were not eligible for 
funded vaccine (M. Batchelor, pers. comm.). However, in 
2010, there were no published data on the relative use of 
monovalent and seasonal vaccines at that time.
The need for rapid implementation of programs results 
in initial studies using immunogenicity, rather than efﬁ  cacy, 
to assess performance of inﬂ  uenza vaccines. After 1 dose 
of monovalent pandemic (H1N1) 2009 vaccine containing 
15 μg hemagglutinin without adjuvant, seroprotection was 
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estimated to be 94%–97% in working-age adults (3,9,10) 
and 75% in children (10). Observational studies provide a 
practical way to calculate vaccine effectiveness under ﬁ  eld 
conditions (11,12). Effectiveness of monovalent pandemic 
(H1N1) 2009 was estimated to be 72%–97% by 3 studies in 
general practice and community-based settings in Europe 
(13–15), 90% in a hospital-based study in Spain (16), and 
100% in a community-based study of children in Canada 
(17). These studies were conducted in populations for 
which the respective local or national pandemic vaccination 
program primarily used vaccine without adjuvant.
We assessed effectiveness of the 2010 seasonal 
inﬂ  uenza vaccine against laboratory-conﬁ  rmed pandemic 
(H1N1) 2009 inﬂ   uenza infection in Victoria, Australia. 
Data came from an established test-negative case–control 
study in a general practitioner sentinel surveillance network 
(18,19).
Methods
Sentinel Surveillance
Victoria is the second most populous state in Australia; 
it has a temperate climate, and the annual inﬂ  uenza season 
usually occurs during May–September. Each season, on 
behalf of the Victorian Government Department of Health, 
the Victorian Infectious Diseases Reference Laboratory 
conducts surveillance for inﬂ   uenza-like illness (ILI; 
deﬁ  ned as history of fever, cough, and fatigue/malaise) 
and laboratory-conﬁ  rmed inﬂ  uenza. General practitioners 
within the network provide weekly reports on case-patients 
with ILI as a proportion of total patients seen and send 
swabs from patients with ILI to the laboratory for testing. 
In 2010, a total of 87 practitioners participated in the 
program, which operated for 25 weeks, from May 3 (week 
19) through October 24 (week 43). Practitioners were asked 
to collect nose and throat swabs from patients with an ILI 
(20) within 4 days after onset of the patient’s symptoms. 
Samples were collected by using Copan dry swabs (Copan 
Italia, Brescia, Italy) and were placed in virus transport 
medium. Practitioners were also asked to provide data on 
the patient’s age, sex, date of symptom onset, vaccination 
status, type of inﬂ  uenza vaccine (monovalent or trivalent/
seasonal) received, and date of vaccination. Type of 
vaccine and date of vaccination were ascertained from 
medical records and patient report.
Laboratory Testing
RNA was extracted from clinical specimens by using 
a Corbett extraction robot (Corbett Robotics, Brisbane, 
Australia), followed by reverse transcription to cDNA by 
using random hexamers. PCR ampliﬁ  cation and detection 
selective for the type A inﬂ  uenza virus matrix gene was 
performed by using primers and a Taqman probe on 
an ABI-7500 Fast Real-Time PCR system (Applied 
Biosystems, Foster City, CA, USA). Samples determined 
to be positive by this assay were conﬁ  rmed as positive or 
negative for pandemic (H1N1) 2009 in a second real-time 
PCR that incorporated primers and probes speciﬁ  c for the 
hemagglutinin gene of the pandemic (H1N1) 2009 virus. 
Inﬂ  uenza B viruses were identiﬁ  ed by a separate PCR. One 
practitioner chose to send samples to the state reference 
laboratory in South Australia for testing with equivalent 
diagnostic assays.
Ascertainment of Case-patients and Controls
Case-patients and controls were sampled prospectively 
throughout the study period. A case-patient was deﬁ  ned as a 
person with ILI for whom test results for pandemic (H1N1) 
2009 were positive; a control was deﬁ  ned as a person with 
negative test results for inﬂ  uenza virus. Analysis of vaccine 
effectiveness against other inﬂ   uenza subtypes was not 
undertaken because of the almost exclusive circulation of 
pandemic (H1N1) 2009 virus during the season; therefore, 
patients with positive test results for other inﬂ  uenza viruses 
were excluded. A control could become a case-patient if 
another illness developed during the season, but a case-
patient was no longer at risk and could not be included 
again.
Data Analysis and Calculation of Vaccine Effectiveness
All analyses were conducted by using Stata version 
10.0 (StataCorp LP, College Station, TX, USA). 
The  χ2 test was used to compare proportions, and the 
Mann-Whitney U test was used to compare time from 
vaccination to time seen by practitioner; p<0.05 was 
considered signiﬁ  cant. Patients were excluded from the 
vaccine effectiveness analysis if vaccination status was 
unknown, if the date of symptom onset was unknown, 
or if the interval between symptom onset and specimen 
collection was >4 days (because of decreased likelihood 
of a positive result after this time) (21,22). Patients 
were considered not vaccinated if time between date of 
vaccination and symptom onset was <14 days. If only the 
month of vaccination was reported, the date of vaccination 
was conservatively estimated to be the last day of the 
month. To avoid overestimation of vaccine effectiveness 
arising from recruitment of controls when inﬂ  uenza was 
not circulating in the population, analysis was restricted 
to case-patients and controls detected within the inﬂ  uenza 
season, deﬁ   ned as the period during which inﬂ  uenza-
positive case-patients were detected (weeks 26–40).
Vaccine effectiveness was deﬁ   ned as (1–odds 
ratio) × 100%; the odds ratio is the odds of laboratory-
conﬁ   rmed pandemic (H1N1) 2009 case-patients having 
been vaccinated divided by the odds of controls having 
been vaccinated. In the test-negative case–control design, 
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the odds ratio estimates the incidence density (rate) ratio 
because controls are selected longitudinally throughout the 
course of the study (i.e., by density sampling) (23,24). The 
odds ratio in test-negative case–control studies has also 
been shown to approximate the risk ratio under conditions 
of varying attack rates and test sensitivity and speciﬁ  city 
(25). Logistic regression was used to calculate odds ratios 
and 95% conﬁ  dence intervals (CIs) for having laboratory-
conﬁ  rmed pandemic (H1N1) 2009, which were adjusted 
for the variables of age group and month of specimen 
collection against  the following: seasonal vaccine, 
monovalent vaccine, both vaccines, and any (either or both 
the seasonal and monovalent) vaccine. Sensitivity analyses 
were conducted to determine the effects of the following 
on vaccine effectiveness: not censoring for specimens 
collected from ILI patients >4 days after symptom onset, 
including controls recruited outside the deﬁ  ned inﬂ  uenza 
season, and assuming that patients with unspeciﬁ  ed type A 
inﬂ  uenza had pandemic (H1N1) 2009.
Ethical Considerations
Data in this study were collected, used and reported 
under the legislative authorization of the Victorian Public 
Health and Wellbeing Act 2008 and Public Health and 
Wellbeing Regulations 2009. Thus, the study did not 
require Human Research Ethics Committee approval.
Results
A total of 172,411 patients were seen by participating 
practitioners during the study period, of whom 678 (0.4%) 
had ILI. After a nadir ILI rate of 0.2% in week 21, the rate 
gradually increased to 0.4% in week 31 before increasing 
more sharply to a peak of 0.9% in week 36. Swabs were 
collected from 478 (71%) ILI patients, among whom 170 
(36%) had positive inﬂ  uenza test results and the remainder 
were negative. Inﬂ  uenza-positive patients were detected 
during weeks 26–40, which was deﬁ  ned as the inﬂ  uenza 
season (Figure). A total of 142 patients were excluded from 
further analysis because vaccination status was unknown 
(n = 11), symptom onset date was unknown (n = 33), time 
between symptom onset and specimen collection was >4 
days (n = 43), or the specimen was collected outside the 
inﬂ  uenza season (n = 82). A signiﬁ  cantly higher proportion 
of inﬂ   uenza-negative patients (13%) than inﬂ  uenza-
positive patients (4%) were excluded because >4 days had 
elapsed between symptom onset and specimen collection (p 
= 0.001). No signiﬁ  cant difference was found by age group 
for whether study participants had a specimen collected 
within 4 days after symptom onset (p = 0.10).
Of the remaining 336 patients, 156 (46%) had positive 
inﬂ  uenza test results. Most (89%) inﬂ  uenza case-patients 
had pandemic (H1N1) 2009, 6% had unspeciﬁ  ed  type 
A inﬂ  uenza, 4% had inﬂ  uenza A (H3N2), and 1% had 
inﬂ   uenza type B (Figure). After exclusion of the other 
inﬂ   uenza patients, 139 pandemic (H1N1) 2009 case-
patients and 180 controls were included in the study 
analysis. Most (57%) participants were 20–49 years of age, 
and case-patients were signiﬁ  cantly younger than controls 
(p = 0.001); no case-patient was >65 years of age (Table 1). 
No statistically signiﬁ  cant difference was found between 
male and female study participants by case or control status 
(p = 0.60) or by vaccination status (p = 0.09). The high 
proportion of case-patients detected in August resulted in 
a signiﬁ  cant difference between case-patients and controls 
by month of swab collection (p<0.001).
Overall, 59 (18%) study participants were reported as 
vaccinated with any vaccine, but the proportion was higher 
among controls (26%) than among case-patients (9%; 
p<0.001). The proportion of controls, who were mostly 
older, who had received the trivalent seasonal vaccine was 
higher than the proportion of controls who had received 
the monovalent vaccine (Table 1). Similarly, controls who 
had received both vaccines were all >20 years of age. Only 
case-patients who were 5–19 and 20–49 years of age were 
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Figure. Inﬂ  uenza status of patients seen at sentinel 
general practices, Victoria, Australia, May 3 (week 
19) through October 24 (week 43), 2010.RESEARCH
reported as vaccinated. Inﬂ   uenza vaccine type was not 
speciﬁ  ed for 1 case-patient and 1 control, each of whom 
was reported as vaccinated.
Reﬂ  ecting the availability of each vaccine, the median 
period between vaccination and visit to a general practitioner 
was signiﬁ  cantly shorter for those who received seasonal 
vaccine (114 days) than for those who received monovalent 
vaccine (223 days; p<0.0001). No signiﬁ  cant difference in 
the time from vaccination to practitioner visit was found 
between case-patients and controls for seasonal (p = 0.70) 
or monovalent vaccine (p = 0.95).
In general, point estimates of vaccine effectiveness 
adjusted for patient age and month of specimen collection 
differed little from crude estimates (Table 2). A signiﬁ  cant 
protective effect was observed for seasonal vaccine only 
(adjusted vaccine effectiveness 79%; 95% CI 33%–93%) 
and seasonal and monovalent vaccines (adjusted vaccine 
effectiveness 81%; 95% CI 7%–96%). The adjusted vaccine 
effectiveness for receipt of any (either or both the seasonal 
and monovalent) vaccine was lower at 67% because of the 
47% vaccine effectiveness for monovalent vaccine. The 
absence of vaccinated case-patients and controls meant 
vaccine effectiveness could not be estimated for several of 
the 5 age groups (Table 1); therefore, age was collapsed 
into 3 variables: children (0–19 years), working-age adults 
(20–64 years), and elderly persons (>65 years). Estimates 
of vaccine effectiveness for working adults were 0%–14% 
higher than the overall adjusted estimates; estimates for 
children were either undeﬁ  ned because no controls were 
vaccinated or were without a signiﬁ  cant protective effect. 
Vaccine effectiveness could not be calculated for elderly 
persons because there were no case-patients in this age 
group.
Sensitivity analyses to determine the effects of certain 
assumptions resulted in variations in the adjusted vaccine 
effectiveness point estimates of 0%–3% and no changes to 
their relative signiﬁ  cance. The effects considered were as 
follows: assumption that those patients with unspeciﬁ  ed 
inﬂ  uenza type A had pandemic (H1N1) 2009, no exclusion 
of patients if >4 days had elapsed between symptom onset 
and specimen collection, and no exclusion of patients if 
they were identiﬁ  ed outside the deﬁ  ned inﬂ  uenza season.
Discussion
Our results indicate that the 2010 seasonal trivalent 
inﬂ   uenza vaccine is >80% effective against pandemic 
(H1N1) 2009 virus, regardless whether given by itself or 
in addition to monovalent vaccine. Groups in Europe and 
Canada have estimated the effectiveness of monovalent 
seasonal inﬂ   uenza vaccine against pandemic (H1N1) 
2009 virus to be 72%–100% (13–17). However, the 
effectiveness of any vaccine (monovalent, seasonal, or 
both) against pandemic (H1N1) 2009 virus was lower 
(67%, 95%  CI 33%–84%) because effectiveness for 
monovalent vaccine only was 47% (95% CI –62% to 
82%). The lower effectiveness of monovalent inﬂ  uenza 
vaccine against pandemic (H1N1) 2009 virus compared 
with seasonal trivalent inﬂ   uenza vaccine is difﬁ  cult  to 
explain. Both vaccines contain the same quantities (15 μg) 
of hemagglutinin; and although the monovalent vaccine 
does not contain adjuvant and was available ≈6 months 
before the seasonal vaccine, it has been shown to be 
strongly immunogenic (3,9,10). Immunogenicity does not 
necessarily correlate directly with vaccine effectiveness, 
and we cannot exclude waning immunity as an explanation 
for the lower effectiveness of monovalent vaccine in our 
study. Waning immunity after receipt of monovalent 
vaccine has been suggested after an interim study from the 
United Kingdom for the 2010–11 inﬂ  uenza season (26). 
The ﬁ  nding could also be a product of the relatively small 
number of case-patients and controls who received only 
the monovalent vaccine, given that vaccine effectiveness 
estimates can change considerably by the inclusion or 
exclusion of 1–2 vaccinated study participants.
When stratiﬁ   ed by age, estimates of vaccine 
effectiveness for working-age adults were higher and 
1184  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 7, July 2011
Table 1. Participants in negative-test case–control study of efficacy of seasonal influenza vaccine for preventing pandemic (H1N1)
2009, Australia, 2010  
Participants
Age group, y  Total,
n = 319  0–4, n = 19  5–19, n = 73  20–49, n = 181  50–64, n = 41  >65, n = 5 
Controls
  Total*  13 (68)  27 (37)  107 (59)  28 (68)  5 (100)  180 (56) 
  Vaccinated with monovalent vaccine†  0 3 (11)  7 (7)  1 (4)  0 11 (6) 
  Vaccinated with seasonal vaccine†  0 0 9 (8)  10 (36)  2 (40)  21 (12) 
  Vaccinated with both vaccines†  0 0 7 (7)  4 (14)  2 (40)  13 (7) 
Pandemic (H1N1) 2009 case-patients 
  Total*   6 (32)  46 (63)  74 (41)  13 (32)  0 139 (44) 
  Vaccinated with monovalent vaccine†  0 3 (7)  3 (4)  0 0 6 (4) 
  Vaccinated with seasonal vaccine†  0 2 (4)  2 (3)  0 0 4 (3) 
  Vaccinated with both vaccines†  0 0 2 (3)  0 0 2 (1) 
*No. (%) study participants. 
†No. (%) controls/pandemic (H1N1) 2009 case-patients. Seasonal Vaccine against Pandemic (H1N1) 2009
more precise than those for children. We previously 
demonstrated that the sentinel practitioner surveillance 
program in Victoria is well suited for estimating vaccine 
effectiveness among working-age adults, who account 
for most of the surveillance population (18), and the 
2010 results were consistent with this observation. The 
relatively few participants in the young (childhood) age 
groups meant the study had insufﬁ  cient power to produce 
deﬁ  ned or signiﬁ  cant estimates of vaccine effectiveness. 
At the other end of the age spectrum, 2% of study 
participants (5 controls and 0 case-patients) in 2010 were 
>65 years of age compared with an average of 7% in this 
age group during 2003–07 (18). Although the absence of 
pandemic (H1N1) 2009 case-patients >65 years of age is 
not surprising, given that older adults have been shown to 
have relatively higher levels of cross-reactive antibodies 
to pandemic (H1N1) 2009 virus (27–29), the reason for 
the low proportion of controls in this age group remains 
unclear. Among the several explanations are a true lower 
rate of ILI in older persons during 2010, a lower rate of 
visits to practitioners for ILI by persons in this age group 
(or treatment at other health services such as hospitals), or 
preferential sampling of younger persons by practitioners 
(and perhaps awareness that pandemic [H1N1] 2009 was 
the predominant circulating inﬂ  uenza virus subtype).
In addition to having a sample size large enough to 
provide vaccine effectiveness estimates by age group 
and inﬂ   uenza type, several other considerations with 
regard to design of case–control studies of inﬂ  uenza 
vaccine effectiveness have been proposed: 1) whether the 
control group best represents the vaccination coverage 
of the source population and 2) whether collection and 
confounding variables have been adjusted for, particularly 
underlying chronic conditions for which vaccine is 
recommended and previous inﬂ  uenza vaccination history 
(30). A 2010 survey of pandemic vaccination suggests that 
monovalent vaccine coverage in the control group was 
generally consistent with that in the general population 
and that use of monovalent vaccine was ≈17% among 
those from Victoria, compared with 13% among controls 
(31). No equivalent survey of 2010 seasonal vaccine 
usage was available for comparison.
Data about concurrent conditions of study participants 
that would indicate need for inﬂ  uenza vaccination were 
not collected during the 2010 inﬂ   uenza season; thus, 
adjustment of the vaccine effectiveness estimates for this 
potentially confounding variable could not be conducted. 
Such confounding by indication (or negative confounding), 
in which persons at higher risk for inﬂ  uenza are more likely 
to be vaccinated, underestimates effectiveness of inﬂ  uenza 
vaccine but may be counteracted by healthy vaccinee bias (or 
positive confounding), which overestimates effectiveness 
(30,32). The extent to which these biases occur is likely to 
vary and may explain the positive and negative variation 
of crude inﬂ   uenza vaccine effectiveness estimates after 
adjustment for chronic conditions in several similar test-
negative case–control studies (33–35). Speculation about 
the relative effects of these biases on how many received 
monovalent vaccine is also difﬁ   cult; vaccination was 
funded for the entire population of Australia, but at the end 
of February 2010, only 18% had been vaccinated (31).
Similar methods using test-negative controls to assess 
seasonal and pandemic vaccine effectiveness against 
both seasonal and pandemic inﬂ  uenza viruses have been 
applied in North America and Europe (13,16,17,33–39). 
Observational studies provide a convenient and timely way 
to assess inﬂ  uenza vaccine effectiveness without the ethical, 
practical, and ﬁ  nancial stringencies associated with clinical 
trials for vaccine efﬁ  cacy, but they also have limitations. 
Modeling suggests that the test-negative case–control 
design generally underestimates true vaccine effectiveness 
under most conditions of test sensitivity, speciﬁ  city, and the 
ratio of inﬂ  uenza to noninﬂ  uenza attack rates (25), although 
quantifying the extent of this effect in this study is difﬁ  cult 
because the precise sensitivity and speciﬁ  city of the test 
are not known. We attempted to limit ascertainment bias 
by censoring records that indicated specimen collection >4 
days after symptom onset and restricting the analysis to 
case-patients and controls tested within the inﬂ  uenza season 
only, although sensitivity analyses indicated little effect 
if these restrictions were relaxed. Of note, these ﬁ  ndings 
apply predominantly to working-age adults receiving 
medical care in the general practice setting; the study did 
not include those who did not seek medical care for ILI. 
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Table 2. Crude and adjusted vaccine effectiveness against pandemic (H1N1) 2009 virus, Australia, 2010  
Effectiveness
Influenza vaccine effectiveness, % (95% confidence interval) 
Seasonal Monovalent Both Any 
Crude 80 (39–93)  42 (62 to 79)  84 (26 to 96)  70 (42 to 84) 
Adjusted*
 0–19  y  Undefined†  44 (231 to 91)  Undefined‡  41 (549 to 69) 
  20–64 y  89 (50 to 98)  56 (88 to 90)  81 (7 to 96)  81 (52 to 92) 
  All ages  79 (33 to 93)  47 (62 to 82)  81 (7 to 96)  67 (33 to 84) 
*Adjusted for month of swab collection. 
†No controls vaccinated. 
‡No controls or case-patients vaccinated. RESEARCH
Thus, the study measured effectiveness of vaccine against 
illness severe enough to require a visit to a practitioner; 
the results cannot necessarily be generalized to other 
parts of the population, in particular young children and 
elderly persons. We were also unable to determine whether 
participants had previously been infected with pandemic 
(H1N1) 2009 virus, which may result in overestimation of 
vaccine effectiveness.
In conclusion, we applied a test-negative case–control 
study design to an established sentinel surveillance system 
to estimate effectiveness of a trivalent seasonal inﬂ  uenza 
vaccine, which included an A/California/7/2009 (H1N1)–
like virus, the pandemic (H1N1) 2009 inﬂ  uenza virus strain. 
This strain is also a component of the trivalent inﬂ  uenza 
vaccine for the 2010–11 Northern Hemisphere inﬂ  uenza 
season (40). The trivalent vaccine provided signiﬁ  cant 
protection against laboratory-conﬁ  rmed pandemic (H1N1) 
2009 virus infection.
Acknowledgments
We thank the general practitioners for participating in the 
surveillance system in 2010, the staff of the Viral Identiﬁ  cation 
Laboratory at the Victorian Infectious Diseases Reference 
Laboratory for conducting the PCRs, and Alain Moren for 
suggestions regarding data analysis.
The General Practitioner Sentinel Surveillance system is 
partly funded by the Victorian Government Department of Health. 
Partial support was also provided by an Australian Government 
National Health and Medical Research Council grant (application 
ID 604925) for research on pandemic (H1N1) 2009 virus to 
inform public policy and by seed funding from the World Health 
Organization.
Mr Fielding is an infectious diseases epidemiologist at 
the Victorian Infectious Diseases Reference Laboratory in 
Melbourne. He is pursuing a PhD in the epidemiology and control 
of seasonal and pandemic inﬂ  uenza at The Australian National 
University. His primary research interests are the epidemiology, 
surveillance, and control of vaccine-preventable diseases.
References
  1.   World Health Organization. World now at the start of 2009 inﬂ  u-
enza pandemic. 2009 Jun 11 [cited 2010 Oct 29]. http://www.
who.int/mediacentre/news/statements/2009/h1n1_pandemic_
phase6_20090611/en/index.html
  2.   World Health Organization. Availability of a candidate reassortant 
vaccine virus for the novel inﬂ  uenza A (H1N1) vaccine develop-
ment. 2009 Jun 4 [cited 2010 Oct 29]. http://www.who.int/csr/
resources/publications/swineﬂ  u/ivr153_20090608_en.pdf
    3.   Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson 
C, Bennet J, et al. Response to a monovalent 2009 inﬂ  uenza A 
(H1N1) vaccine. N Engl J Med. 2009;361:2405–13. doi:10.1056/
NEJMoa0907413
  4.   Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 
pandemic inﬂ  uenza A (H1N1) virus. N Engl J Med. 2009;361:2591–
4. doi:10.1056/NEJMp0910445
  5.   Australian Government Department of Health and Ageing. Get vac-
cinated. 2009 [cited 2010 Oct 29]. http://www.ﬂ  upandemic.gov.au/
internet/panﬂ  u/publishing.nsf/Content/H1N1%202009-1
  6.   World Health Organization. Recommended composition of inﬂ  u-
enza virus vaccines for use in the 2010 inﬂ  uenza season (Southern 
Hemisphere winter). Wkly Epidemiol Rec. 2009;84:421–31.
  7.   Australian Government Department of Health and Ageing. Inﬂ  u-
enza (ﬂ  u) [cited 2010 Oct 29]. http://www.immunise.health.gov.au/
internet/immunise/publishing.nsf/Content/immunise-inﬂ  uenza
  8.   National Health and Medical Research Council. The Australian im-
munisation handbook. 9th ed. Canberra (ACT, Australia): Australian 
Government Department of Health and Ageing; 2008.
  9.   Wu J, Li W, Wang HQ, Chen JT, Lv M, Zhou JC, et al. A rapid im-
mune response to 2009 inﬂ  uenza A(H1N1) vaccines in adults: a ran-
domized, double-blind, controlled trial. J Infect Dis. 2010;202:675–
80. doi:10.1086/655226
10.   Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A 
novel inﬂ  uenza A (H1N1) vaccine in various age groups. N Engl J 
Med. 2009;361:2414–23. doi:10.1056/NEJMoa0908535
11.   Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, 
Bart KJ, et al. Field evaluation of vaccine efﬁ  cacy. Bull World 
Health Organ. 1985;63:1055–68.
12.   Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efﬁ  cacy 
in the ﬁ  eld. Further observations. Epidemiol Rev. 1988;10:212–41.
13.   Kissling E, Valenciano M, Cohen J, Oroszi B, Barret A, Rizzo C, 
et al. Estimates of pandemic inﬂ  uenza vaccine effectiveness in Eu-
rope, 2009–10: results of I-MO vaccine effectiveness multicentre 
case–control study. In: Abstract book for Options for the Control of 
Inﬂ  uenza VII; 2010 Sep 3–7; Hong Kong SAR, China.
14.   Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hel-
lenbrand W, et al. Pandemic inﬂ  uenza A(H1N1) 2009 breakthrough 
infections and estimates of vaccine effectiveness in Germany 2009–
2010. Euro Surveill. 2010;15:pii:19561.
15.   Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, 
Sebastian Pillai P, et al. Effectiveness of pandemic and seasonal in-
ﬂ  uenza vaccine in preventing inﬂ  uenza A (H1N1)2009 infection in 
England and Scotland 2009–2010. Euro Surveill. 2011;16:pii:19763.
16.   Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer 
MD, Perez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of 
seasonal 2008–2009, 2009–2010 and pandemic vaccines, to pre-
vent inﬂ  uenza hospitalizations during the autumn 2009 inﬂ  uenza 
pandemic wave in Castellon, Spain. A test-negative, hospital-
based, case–control study. Vaccine. 2010;28:7460–7. doi:10.1016/j.
vaccine.2010.09.042
17.    Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, 
Minville-Leblanc M, Garceau R, et al. Protective effect of single-
dose adjuvanted pandemic inﬂ   uenza vaccine in children. Inﬂ  u-
enza Other Respi Viruses. 2010;4:171–8. doi:10.1111/j.1750-
2659.2010.00146.x
18.   Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of 
inﬂ  uenza vaccine effectiveness from routine surveillance data. PLoS 
ONE. 2009;4:e5079. doi:10.1371/journal.pone.0005079
19.   Kelly H, Grant K. Interim analysis of pandemic inﬂ  uenza (H1N1) 
2009 in Australia: surveillance trends, age of infection and effective-
ness of seasonal vaccination. Euro Surveill. 2009;14:pii:19288.
20.  Thursky K, Cordova SP, Smith D, Kelly H. Working towards a 
simple case deﬁ   nition for inﬂ   uenza surveillance. J Clin Virol. 
2003;27:170–9. doi:10.1016/S1386-6532(02)00172-5
21.    Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, 
Leach S, et al. Time lines of infection and disease in human in-
ﬂ  uenza: a review of volunteer challenge studies. Am J Epidemiol. 
2008;167:775–85. doi:10.1093/aje/kwm375
1186  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 7, July 2011Seasonal Vaccine against Pandemic (H1N1) 2009
22.   Cowling BJ, Chan KH, Fang VJ, Lau LL, So HC, Fung RO, et al. 
Comparative epidemiology of pandemic and seasonal inﬂ  uenza 
A in households. N Engl J Med. 2010;362:2175–84. doi:10.1056/
NEJMoa0911530
23.   Pearce N. What does the odds ratio estimate in a case–control study? 
Int J Epidemiol. 1993;22:1189–92. doi:10.1093/ije/22.6.1189
24.   Rodrigues L, Kirkwood BR. Case–control designs in the study of 
common diseases: updates on the demise of the rare disease assump-
tion and the choice of sampling scheme for controls. Int J Epidemiol. 
1990;19:205–13. doi:10.1093/ije/19.1.205
25.   Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gar-
giullo P, et al. Methodologic issues regarding the use of three obser-
vational study designs to assess inﬂ  uenza vaccine effectiveness. Int 
J Epidemiol. 2007;36:623–31. doi:10.1093/ije/dym021
26.   Pebody R, Hardelid P, Fleming DM, McMenamin J, Andrews N, 
Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic 
inﬂ  uenza A(H1N1)2009 vaccines in preventing inﬂ  uenza infection 
in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 
2011;16:pii:19791.
27.   Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. 
Cross-reactive antibody responses to the 2009 pandemic H1N1 
inﬂ  uenza virus. N Engl J Med. 2009;361:1945–52. doi:10.1056/
NEJMoa0906453
28.   Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon 
M. Incidence of 2009 pandemic inﬂ  uenza A H1N1 infection in Eng-
land: a cross-sectional serological study. Lancet. 2010;375:1100–8. 
doi:10.1016/S0140-6736(09)62126-7
29.   Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dw-
yer DE, et al. Inﬂ  uenza A (H1N1) 2009 antibodies in residents of 
New South Wales, Australia, after the ﬁ  rst pandemic wave in the 
2009 Southern Hemisphere winter. PLoS ONE. 2010;5:e12562. 
doi:10.1371/journal.pone.0012562
30.   Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs 
for timely estimation of inﬂ  uenza vaccine effectiveness using Eu-
ropean sentinel practitioner networks. Vaccine. 2010;28:7381–8. 
doi:10.1016/j.vaccine.2010.09.010
31.  Australian Institute of Health and Welfare. 2010 pandemic vaccina-
tion survey: summary results. Canberra (ACT, Australia): Australian 
Government Australian Institute of Health and Welfare; 2010.
32.   Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confound-
ing by indication in non-experimental evaluation of vaccine ef-
fectiveness: the example of prevention of inﬂ  uenza complications. 
J Epidemiol Community Health. 2002;56:951–5. doi:10.1136/
jech.56.12.951
33.   Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, 
et al. Estimating vaccine effectiveness against laboratory-conﬁ  rmed 
inﬂ  uenza using a sentinel physician network: results from the 2005–
2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 
2007;25:2842–51. doi:10.1016/j.vaccine.2006.10.002
34.    Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, 
Fonseca K, et al. Component-speciﬁ   c effectiveness of trivalent 
inﬂ   uenza vaccine as monitored through a sentinel surveillance 
network in Canada, 2006–2007. J Infect Dis. 2009;199:168–79. 
doi:10.1086/595862
35.   Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Bouli-
anne N, Hottes TS, et al. Association between the 2008–09 seasonal 
inﬂ  uenza vaccine and pandemic H1N1 illness during spring–sum-
mer 2009: four observational studies from Canada. PLoS Med. 
2010;7:e1000258. doi:10.1371/journal.pmed.1000258
36.   Savulescu C, Valenciano M, de Mateo S, Larrauri A. Estimating the 
inﬂ  uenza vaccine effectiveness in elderly on a yearly basis using the 
Spanish inﬂ  uenza surveillance network—pilot case–control studies 
using different control groups, 2008–2009 season, Spain. Vaccine. 
2010;28:2903–7. doi:10.1016/j.vaccine.2010.01.054
37.   Fleming DM, Andrews NJ, Elllis JS, Bermingham A, Sebastianpillai 
P, Elliot AJ, et al. Estimating inﬂ  uenza vaccine effectiveness using 
routinely collected laboratory data. J Epidemiol Community Health. 
2010;64:1062–7. doi:10.1136/jech.2009.093450
38.    Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, 
Foust A, et al. Effectiveness of inactivated inﬂ  uenza  vaccines 
varied substantially with antigenic match from the 2004–2005 
season to the 2006–2007 season. J Infect Dis. 2009;199:159–67. 
doi:10.1086/595861
39.   Centers for Disease Control and Prevention. Interim within-season 
estimate of the effectiveness of trivalent inactivated inﬂ  uenza vac-
cine—Marshﬁ  eld, Wisconsin, 2007–08 inﬂ  uenza season. MMWR 
Morb Mortal Wkly Rep. 2008;57:393–8.
40.    World Health Organization. Recommended viruses for inﬂ  uenza 
vaccines for use in the 2010–2011 Northern Hemisphere inﬂ  uenza 
season. Wkly Epidemiol Rec. 2010;85:81–92.
Address for correspondence: James E. Fielding, 10 Wreckyn St, North 
Melbourne, Victoria 3051, Australia; email: james.ﬁ  elding@mh.org.au
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 7, July 2011  1187
Use of trade names is for identiﬁ  cation only and does not 
imply endorsement by the Public Health Service or by the US 
Department of Health and Human Services.
http://www.facebook.com/ 